Computational reactive-diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
24 07 2023
24 07 2023
Historique:
received:
22
02
2023
accepted:
14
07
2023
medline:
26
7
2023
pubmed:
25
7
2023
entrez:
24
7
2023
Statut:
epublish
Résumé
Mathematical models based on partial differential equations (PDEs) can be exploited to handle clinical data with space/time dimensions, e.g. tumor growth challenged by neoadjuvant therapy. A model based on simplified assessment of tumor malignancy and pharmacodynamics efficiency was exercised to discover new metrics of patient prognosis in the OLTRE trial. We tested in a 17-patients cohort affected by early-stage triple negative breast cancer (TNBC) treated with 3 weeks of olaparib, the capability of a PDEs-based reactive-diffusive model of tumor growth to efficiently predict the response to olaparib in terms of SUV
Identifiants
pubmed: 37488154
doi: 10.1038/s41598-023-38760-z
pii: 10.1038/s41598-023-38760-z
pmc: PMC10366144
doi:
Substances chimiques
diethylstilbestrol monophosphate
47341-71-9
Ki-67 Antigen
0
olaparib
WOH1JD9AR8
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11951Informations de copyright
© 2023. The Author(s).
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Cancer Res. 1988 Dec 15;48(24 Pt 1):7067-71
pubmed: 3191483
Cancer Res. 2015 Nov 15;75(22):4697-707
pubmed: 26333809
Cancers (Basel). 2021 Sep 03;13(17):
pubmed: 34503265
J Clin Oncol. 2020 Feb 10;38(5):388-394
pubmed: 31461380
Theory Biosci. 2021 Jun;140(2):197-203
pubmed: 33988848
NPJ Breast Cancer. 2022 Jul 19;8(1):85
pubmed: 35853907
Front Oncol. 2021 Jun 28;11:686776
pubmed: 34262869
Surg Clin North Am. 2023 Feb;103(1):83-92
pubmed: 36410355
Ann Oncol. 2019 Dec 1;30(12):1941-1949
pubmed: 31566659
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Lancet Oncol. 2021 Jun;22(6):858-871
pubmed: 34019819
Philos Trans R Soc Lond B Biol Sci. 2015 Apr 19;370(1666):
pubmed: 25750242
Eur J Cancer. 2021 Jul;152:4-17
pubmed: 34062485
Ann Oncol. 2014 Mar;25(3):611-618
pubmed: 24401929
Am Health Drug Benefits. 2016 Feb;9(1):23-32
pubmed: 27066193
Semin Cancer Biol. 2018 Oct;52(Pt 2):16-25
pubmed: 29024776
Clin Genet. 2014 Jul;86(1):62-7
pubmed: 24635704
Scand J Clin Lab Invest Suppl. 2010;242:6-14
pubmed: 20515269
Nat Rev Clin Oncol. 2016 Apr;13(4):242-54
pubmed: 26598946
Ann Oncol. 2021 Oct;32(10):1216-1235
pubmed: 34242744
PLoS One. 2014 Jan 03;9(1):e83962
pubmed: 24404145
Prog Cardiovasc Dis. 2015 May-Jun;57(6):607-14
pubmed: 25560327
Cancer Treat Rev. 2022 Dec;111:102468
pubmed: 36202026
J Clin Oncol. 2019 Mar 1;37(7):559-569
pubmed: 30650045
Nat Cancer. 2022 Aug;3(8):927-931
pubmed: 35788722
Biochem Soc Trans. 2017 Feb 8;45(1):229-236
pubmed: 28202677
Eur J Cancer. 2021 May;149:134-152
pubmed: 33862496
Am Soc Clin Oncol Educ Book. 2017;37:160-169
pubmed: 28561651
Ann Biomed Eng. 2016 Sep;44(9):2626-41
pubmed: 27384942
Comput Methods Appl Mech Eng. 2017 Feb 1;314:494-512
pubmed: 28042181
Cancer Manag Res. 2019 Aug 07;11:7525-7536
pubmed: 31616176
Expert Rev Anticancer Ther. 2018 Dec;18(12):1271-1286
pubmed: 30252552
J Clin Oncol. 2022 Jul 20;40(21):2361-2374
pubmed: 35353548
Invest New Drugs. 2013 Aug;31(4):949-58
pubmed: 23315029
Ann Oncol. 2019 Aug 1;30(8):1194-1220
pubmed: 31161190
J Law Med Ethics. 2019 Sep;47(3):357-361
pubmed: 31560620
Bull Math Biol. 2019 Jun;81(6):1965-2010
pubmed: 30903592
Breast Cancer Res. 2012 Jan 06;14(1):R3
pubmed: 22225836
N Engl J Med. 2021 Jun 24;384(25):2394-2405
pubmed: 34081848
Nat Clin Pract Oncol. 2009 Jan;6(1):34-42
pubmed: 18852721